56 results about "Liver necrosis" patented technology

The invention belongs to the technical field of medicinal chemistry, and discloses a preparation method and application of a 5-aryl substituted 1, 2, 4-triazole iron death inhibitor derivative. The derivative has a structural general formula as shown in the following formula (I), wherein Ar1 and Ar2 substituent groups can be combined at will. The compound can be used for efficiently removing cell lipid peroxides and effectively inhibiting ferroptosis processes of various cells. Particularly, the compound SN26 has optimal ferroptosis inhibitory activity (786-O cell line, EC50 = 62nM), and can effectively improve acute liver injury of mice caused by concanavalin by inhibiting ferroptosis. The research is expected to be used for developing ferroptosis inhibitors and research and development of small molecule drugs for related diseases. # imgabs0 #

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

In the present specification, disclosed is a method for preparing a gallocatechin gallate (Gallocatable Gallate), which comprises the steps of: preparing a gallocatechin gallate (Gallocatable Gallate; the present invention relates to uses of a composition for enhancing liver health or for auxiliary protection against chemical liver injury, in particular to uses of a composition for enhancing liver health or for auxiliary protection against chemical liver injury, such as GCG, isoquercitrin, IQC, and to the preparation of a composition for enhancing liver health or for auxiliary protection against chemical liver injury. In one aspect, the composition of the present invention can include a composite component of gallocatechin gallate and isoquercitrin to effectively reduce oxidative stress and chronic inflammatory response occurring in the process of lipid accumulation in liver tissue to improve liver health, and is applied to prevention, improvement or treatment of various liver diseases such as hepatitis, cirrhosis, liver cancer and the like.

The present application relates to the technical field of medicine, and discloses application of gastrodin in preparation of medicine for preventing and treating radioactive liver injury, wherein the radioactive liver injury is liver injury caused by ionizing radiation exposure. It is found that the gastrodin can effectively intervene in specific mechanism of the radioactive liver injury, significantly reduce the mortality of the radioactive liver injury mice, reverse the hepatic veno-occlusive disease and the core pathological features of liver fibrosis of the radioactive liver injury, and more specifically treat the radioactive liver injury. On the other hand, the gastrodin can be used before radiation exposure to prevent serious radioactive liver injury after radiation exposure.

The invention discloses a meconopsis integrifolia liver-protecting pharmacodynamic component group screening and verification method and system, and belongs to the field of pharmaceutical analys.The method mainly comprises the steps that meconopsis integrifolia total flavonoid components and total alkaloid components are extracted; measuring the content of total flavonoid components and total alkaloid components of meconopsis integrifolia; cCl4 is adopted to induce HepG2 human hepatoma carcinoma cell injury for modeling, the expression level of a corresponding liver injury index is detected, and in-vitro screening is carried out on a pharmacodynamic component group; cCl4 is adopted to induce acute liver injury of KM mice for modeling, corresponding liver injury indexes and the expression level of inflammatory factors are detected, and screened pharmacodynamic component groups are subjected to in-vivo verification. According to the invention, in vitro screening is carried out on the medicinal component groups with the liver protection effect in meconopsis integrifolia, then the liver protection effects of different component groups are verified at the in vivo level, the screening accuracy of the medicinal component groups is ensured, and meanwhile, a modern infrared spectroscopic analysis technology is combined to characterize and predict the disease characteristics to a certain extent, so that the screening accuracy of the medicinal component groups is improved. And rapid identification and disease prediction are facilitated.

The invention discloses an application of harpagoside in preparation of a medicine for preventing and / or treating hepatic fibrosis. The invention discloses an application of harpagoside in preparation of a health care product with an auxiliary protection effect on chemical liver injury. The animal level proves that the harpagoside can reduce hepatic fibrosis such as chemical hepatic fibrosis induced by carbon tetrachloride, reduce liver collagen deposition, reduce hydroxyproline content in hepatic tissue, reduce increased HA and Col IV content in serum, and reduce expression of fibrosis and collagen deposition related genes, so that the harpagoside can be used for treating hepatic fibrosis. The traditional Chinese medicine composition has a good effect of treating or preventing hepatic fibrosis.

The invention discloses an application of 5-methoxyl serotonin in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and systematically proves that the 5-methoxyl serotonin (5MOS) has the effects of relieving hepatic fibrosis, improving accumulation of bile acid in the liver and reversing metabolism and transport of the bile acid for the first time, so that the cholestatic liver diseases can be prevented and / or treated by the 5-methoxyl serotonin (5MOS). DDC-induced cholestatic liver injury is relieved in a dose-dependent manner, and a new medication strategy is provided for treating cholestatic liver diseases.

The invention provides an application of IL-19 (interleukin-19) in preparation of a medicine for preventing or treating drug-induced liver injury. In the invention, the IL-19 protein, or the derivative or variant thereof, or the enhancer thereof, or the expression vector thereof can significantly improve the drug-induced liver injury, especially APAP-induced mouse liver injury, for example, the levels of ALT and AST are reduced, the liver necrosis area is reduced, the levels of inflammatory factors such as Tnfa, Il1b, Il6 and Ccr2 are reduced, the infiltration number of liver inflammatory cells is reduced, and the like.

The application belongs to the technical field of biomedicine, and discloses a method for constructing a Channa argus bile stasis model. The application discloses application of rifampicin or a pharmaceutically acceptable salt thereof in construction of a fish liver injury model. The application discloses, for the first time, that the antibiotic rifampicin widely used in aquaculture is used to construct a fish liver injury model. The model is closer to the real scene of the use of a large amount of drugs when bacterial diseases break out in production practice. The injury type of the fish liver injury model is clearly directed to bile stasis, which fills the research blank of the disease model of the fish, and is different from common hepatocyte necrosis or fatty liver models.

The present application relates to a kind of VSIG4 based on reversible immunological affinity magnetic bead separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation The isolated cells of the present application can reduce liver inflammation and injury, and effectively treat acute liver injury and acute liver failure. The isolation method of the present application is fast, mild and efficient, and the obtained cells are functional and suitable for adoptive cell therapy, which has a broad clinical application prospect.

The present invention discloses the use of an acetyl-CoA (Ac‑CoA) promoter in the preparation of a drug for promoting liver regeneration. The present invention utilizes a mouse partial hepatectomy model and administers GS‑0976 before hepatectomy to increase Ac‑CoA in the liver. The results show that increased Ac‑CoA in the liver has the ability to improve liver function after liver injury and promote hepatocyte proliferation. The mechanism involves Ac‑CoA promoting MSL1 phase separation, increased STAT3 and H4K16 acetylation, which manifests as significantly upregulated cell cycle-related genes and increased hepatocyte proliferation. The experimental results show that increasing liver Ac‑CoA levels has the effect of promoting liver regeneration, providing a new solution for the recovery and treatment of hepatectomy and its complications.

Disclosed in the present invention are an iodine-131-labeled small-molecule polypeptide TFMP-Y2, and a preparation method therefor and the use thereof. In the present invention, on the basis of the Caerin 1.9 polypeptide and by performing modification to enhance the water solubility of the polypeptide and reduce the inhibitory effect of the polypeptide on the proliferation of normal cells, a new small-molecule polypeptide TFMP-Y2 is obtained. The TFMP-Y2 polypeptide alone has no significant inhibitory effect on the proliferation of normal cells and HGC-27. However, 131I-TFMP-Y2 can be stably retained in gastric carcinoma cells, and has a significant anti-tumor effect. Moreover, the water-soluble 131I-TFMP-Y2 is mainly excreted by the renal urinary system, such that the risk of radioactive liver damage caused by 131I-Caserin 1.9 can be reduced. Therefore, TFMP-Y2 is a good small-molecule polypeptide for introducing a nuclide into the body, which improves the drug safety and the tumor targeting property, and can be used as a potential drug for internal radiation therapy of tumors.

The invention relates to the field of biological medicines, and discloses application of an OGG1 micromolecule agonist in preparation of a medicine for treating liver inflammatory diseases. According to the micromolecule TH10785, by activating the beta, delta-lyase activity of DNA repair enzyme OGG1, the oxidized DNA repair capacity is remarkably enhanced, ROS accumulation in liver cells is reduced, NF-kappa B signal channel activation and proinflammatory factor release are inhibited, and therefore liver inflammation and fibrosis are effectively relieved. Meanwhile, the medicine can inhibit the activation of B cells and the formation of plasma cells, finally reduces the generation of autoimmune antibodies, and improves the immune imbalance state of autoimmune hepatitis. The invention provides an innovative treatment strategy based on OGG1 enzyme function amplification, and a new pharmacological approach is provided for treatment of chronic liver diseases and immunological liver injury.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

The invention discloses application of an APOA5 inhibitor in prevention and treatment of PD-L1 high expression liver diseases and screening of drugs for regulating liver immune inflammatory microenvironment homeostasis. The APOA5 inhibitor reduces and / or inhibits at least one of expression, secretion and activity of APOA5. The application finds that the expression level of PD-L1 (especially the expression level of macrophage PD-L1) is reduced by knocking down APOA5, and the APOA5 can be applied to reduction of liver cell apoptosis, reduction of the level of macrophage inflammatory factors and prevention and treatment of PD-L1 high-expression related diseases such as sepsis acute liver injury.

The invention discloses application of solamargine in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. By simulating a classical Mdr2- / -mouse model of clinical cholestasis pathology, the solamargine is researched and proved to treat cholestatic liver injury by improving hepatocyte injury, bile duct dysfunction and bile metabolism disorder, and the solamargine shows good application potential in clinical treatment of cholestatic liver diseases.

The present application belongs to the technical field of medicine, and relates to a kind of pharmaceutical composition and its application in preparation for treating or preventing liver fibrosis drug. A kind of pharmaceutical composition for treating or preventing liver fibrosis, the pharmaceutical composition includes as active ingredient the protocatechuic acid (PCA) and gimalin (GER). The present application first confirms that protocatechuic acid and gimalin combined application has significant synergistic effect in the treatment of liver fibrosis, and its curative effect is better than any single compound single administration, can more effectively reduce liver injury index, improve liver pathological morphology, reduce intrahepatic collagen deposition. Based on its clear mechanism of action, the composition of the present application is especially suitable for treating liver fibrosis related to abnormal expression of RIPK3.

The invention discloses a biomarker composition and application thereof. The biomarker combination comprises a hepatitis B capsid antibody complex and glutamic-pyruvic transaminase. The biomarker combination provided by the invention has high specificity and sensitivity when being used for diagnosing chronic hepatitis B, predicting prognosis of chronic hepatitis B and / or evaluating liver injury caused by chronic hepatitis B. If ALT is normal (llt; according to the present invention, the potential intrahepatic inflammation can still be significantly detected in chronic hepatitis B patients (e.g., 40 IU / L) patients, can be adopted as the non-invasive biomarker for evaluating the hepatic inflammation in chronic hepatitis B patients, and can accurately reflect the intrahepatic inflammation level of chronic hepatitis B patients so as to provide the effective basis for the start of the antiviral treatment.

The present application relates to the technical field of biotechnology, and particularly relates to a lysosome-targeted calcium ion fluorescent probe and application thereof. The calcium ion fluorescent probe provided by the present application has high sensitivity fluorescent response to calcium ions, and is not interfered by pH, and can be used for monitoring dynamic changes of lysosome calcium ions. Meanwhile, the lysosome calcium ion fluorescent probe in the present application has good biocompatibility, low background fluorescent interference and other advantages, makes up for the deficiency of traditional commercialized calcium ion fluorescent probes, and has wide application prospect in the field of acute liver injury and other liver diseases in vivo.

The invention belongs to the technical field of protein functions and application, and particularly relates to application of TIPE2 protein in preparation of a preparation for inhibiting iNKT cell activation, and a nucleotide sequence for coding the TIPE2 protein is shown as SEQ ID NO.1. The TIPE2 protein provided by the invention can prevent excessive activation of iNKT cells to avoid further autoimmune diseases. The key effect of the TIPE2 in liver related diseases is expanded, and the unknown value of the TIPE2 in the iNKT cell biological function of immune-mediated liver injury is disclosed. It is proved that the TIPE2 is a key regulatory factor of liver homeostasis, and a clue is provided for the TIPE2 to become a potential therapeutic target for regulating immune-mediated liver injury.

The present invention discloses the use of fotantinib in treating severe dengue fever liver damage, belonging to the field of biotechnology. The present invention provides the use of fotantinib or a pharmaceutically acceptable salt thereof in preparing a pharmaceutical composition for preventing or treating dengue fever liver damage, and in preparing a pharmaceutical composition for regulating the carbon metabolism of hepatocytes in patients infected with dengue virus. The present invention also provides a method for regulating the level of in vitro dengue virus-infected hepatocyte damage, and for screening a pharmaceutical method for assisting fotantinib or a pharmaceutically acceptable salt thereof in treating and preventing dengue fever liver damage.

This invention relates to the field of biomedicine, specifically to the application of dimethylhydroquinone in improving ischemia-reperfusion-related injury of the heart and liver. 2,6-DMHQ can reduce serum ALT and AST, improve liver necrosis, and also reduce serum myocardial enzyme levels CK, CK / MB, and LDH, thereby reducing the area of ​​myocardial infarction.

The invention discloses a bacterial strain with effects of protecting liver and expelling toxins and application of the bacterial strain. The bacterial strain is Bifidobacterium animalis BL03, is preserved in Guangdong Microbial Culture Collection Center, and has the preservation number of GDMCC NO.64840. The bacterial strain has the effects of protecting liver and expelling toxins and the application of the bacterial strain. The preservation time is July 8, 2024; the strain with the effects of protecting the liver and expelling toxins can relieve liver injury, can reduce the content of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in serum, and can achieve the effects of protecting the liver and expelling toxins.

The invention relates to an application of a specific excitation Mas receptor in a medicine for preventing and treating hepatic ischemia-reperfusion injury. According to the invention, a G protein coupled receptor Mas coded by a protooncogene Mas1 is focused, a 70% warm ischemia reperfusion model of the liver is constructed by clamping left and middle leaf vessels of the liver by a vascular clamp after a mouse is laparotomy, and the condition that the liver injury can be obviously alleviated by activating the Mas receptor and the liver injury can be aggravated by knocking out the Mas receptor is fully proved on an in-vivo level; the invention provides an important early-stage data basis for research and development of new drugs based on specific activation of the Mas receptor, and is expected to provide an important animal experiment basis for development of new drugs aiming at the Mas receptor in a later stage.

The invention relates to the technical field of medicines, and discloses application of gastrodin in preparation of a medicine for preventing and treating radioactive liver injury, and the radioactive liver injury is liver injury caused by ionizing radiation exposure. The gastrodin is found to be capable of effectively intervening a specific mechanism of the radiation-induced liver injury, so that the death rate of mice with the radiation-induced liver injury is remarkably reduced, meanwhile, the core pathological characteristics of hepatic vein occlusion and hepatic fibrosis of the radiation-induced liver injury are reversed, and the radiation-induced liver injury is treated in a more targeted manner. On the other hand, gastrodin is used before radiation exposure, so that serious radioactive liver injury after radiation exposure can be prevented.

The invention provides a traditional Chinese medicine composition for hepatic nodule and a preparation method and application thereof, and relates to the field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition for cirrhosis nodules. Comprising the following raw materials in parts by weight: 3-40 parts of radix salviae miltiorrhizae, 5-20 parts of radix paeoniae alba, 3-25 parts of rhizoma cyperi, 5-30 parts of poria cocos, 3-20 parts of fructus gardeniae, 3-19 parts of pericarpium citri reticulatae viride, 5-18 parts of fructus aurantii, 3-25 parts of radix aucklandiae, 3-40 parts of endothelium corneum gigeriae galli, 5-25 parts of fructus amomi, 3-26 parts of rhizoma corydalis, 5-16 parts of cortex magnoliae officinalis, 3-19 parts of betel nuts, 3-30 parts of rhizoma alismatis, 3-12 parts of liquorice, 5-50 parts of herba artemisiae scopariae, 5-30 parts of radix isatidis and 3-25 parts of massa medicata fermentata fujianensis. The traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, replenishing qi to invigorate the spleen, soothing the liver, removing stasis and the like, strengthens the body resistance, eliminates evil and can obviously reduce the volume of cirrhosis nodules, and the curative effect is good. Moreover, the traditional Chinese medicine composition can enhance the oxidative stress resistance of liver cells, inhibit hepatic fibrosis, avoid liver injury, regulate the metabolic microenvironment and improve the immune balance.

According to a sepsis mouse model, it is found that phytolaccin can reduce the liver necrosis area and the inflammatory focus caused by sepsis by reducing the content of alanine aminotransferase, glutamic oxalacetic transaminase, serum creatinine and lactic dehydrogenase, so that the application of phytolaccin to preparation of the medicine for treating sepsis is achieved, and the application of phytolaccin to preparation of the medicine for treating sepsis is achieved. The lung inflammation, alveolar wall thickening and inflammatory cell infiltration are improved, so that the organ injury caused by sepsis is relieved. Meanwhile, the phytolaccin can also regulate the polarization state of macrophages to a balanced state in an inflammatory storm state, so that the release of proinflammatory factors is inhibited, and the effect of preventing and treating sepsis is achieved.

The present invention relates to the technical field of probiotic application, and in particular to a Lactobacillus plantarum LP4 capsule polysaccharide extract and its application. The preparation method of the Lactobacillus plantarum LP4 capsule polysaccharide extract comprises: taking Lactobacillus plantarum ( Lactobacillus plantarum ) LP4 was fermented and cultured, the fermentation liquid was centrifuged, the bacteria were collected, and hot water extraction was performed. The extract was centrifuged, the supernatant was collected, and crude polysaccharides were obtained by ethanol precipitation; after deproteinization with trichloroacetic acid, dialyzation was performed using a 7000Da dialysis bag, and the retained material was vacuum freeze-dried to obtain the Lactobacillus plantarum LP4 capsular polysaccharide extract. The Lactobacillus plantarum LP4 capsular polysaccharide extract can significantly reduce the triglyceride and total cholesterol content in the serum and liver of obese mice, and alleviate the liver amino acid metabolism disorder caused by a high-fat diet, and effectively reduce liver damage caused by a high-fat diet.